I-Patiromer entsha yeDrug Shows iThembisa ukuPhatha i-Hyperkalemia
Isiza esitsha esibizwa ngokuba yi-Patiromer siye sabonisa isithembiso ekuphatheni i-hyperkalemia kubantu abathatha inqubo ye-renim-angiotensin-aldosterone (RAAS). I-Hyperkalemia isongela ubomi kwaye ibangela ubuthathakathaka, inyuke ukukhubazeka, ukungaphumeleli kokuphefumula, kunye nokungaqhelekanga komzimba.
Ngamanye amaxesha, abantu abakhona nge-hyperkalemia, okanye amazinga ephakamileyo e-potassium egazini, kwiikliniki ezingaphandle.
Aba bantu bakhulu kwaye banesifo sesifo sesifo sikashukela kunye ne-hyperkalemia emva kokuba bathathe i-renin-angiotensin-aldosterone system (RAAS) inhibitors (i-β-blockers, i-angiotensin-guqula i-inhibitors ye-enzyme, i-angiotensin receptor blockers [ARBs] kunye ne-aldosterone receptor blockagonists) Kwizigulane ezinokukhubazeka kwe-renal okanye i-nephropathy yesifo sikashukela, amanqanaba e-potassium anyuselwa kumazinga anobungozi emva kokulawulwa kwama-inhibitors we-RAAS, okwenza i-potassium ingabikho kwi-urine.
Uninzi, nangona kunjalo, i-hyperkalemia yinto edla ngokubanzi phakathi kwezigulane zasezibhedlele eziphathwe nge-RAAS inhibitors ngenxa yesifo senhliziyo, isifo sikashukela, nesifo sesifo esingasasigxina. Isifo sikashukela kunye nesifo esingasigxina sesifo kubangelwa i-atherosclerosis kunye ne-glomerulosclerosis, ngokulandelanayo; ezi nkqubo zentsholongwane zisebenza kunye ukuze zivimbele umzimba (iinjongo) ukukwazi ukuzinqumla i-potassium.
Nangona i-RAAS inhibitors i-potassium-sparing kwaye ingakhokelela kumanqanaba aphezulu e-potassium okanye i-hyperkalemia, ukuhluleka kwentliziyo, isifo esingasigxina nesifo sikashukela siphathwa nge-RAAS inhibitors. Ngaloo ndlela, kuya kuba luncedo ukufumana indlela efanelekileyo yokunyanga i-hyperkalemia kubantu abaneemimiselo ezithatha i-RAAS inhibitors.
Okwangoku, i- hyperkalemia iye yaphathwa kuphela ngeendlela ezinje nje nge-beta agonists, calcium, okanye i-insulin kunye ne-glucose, zonke ezihambisa i-potassium kwiiseli; i-loop okanye i-thiazide diuretics, zombini ezo i-potassium ezichithayo kwaye zandisa ukwanda kwe-potassium; iziyobisi ezibizwa ngokuba yi-sodium polystyrene sulfonate (i-Kayexalate), engabangela i-hypomagnesemia, i-hypokalemia, ingcinezelo yesisu esiswini kunye ne-necrosis; kunye ne-dialysis. Kwixesha leemvavanyo zecandelo lesi-3, i-Patiromer iyanciphisa kakhulu izinga le-potassium kwizigulane ezinezifo zesifo sesifo sesifo sikashukela esathatha i-RAAS inhibitors kwaye sathuthuka sine-hyperkalemia.
I-Patiromer yenziwe yipolymer eyadlula kwi-tract static tract. Ngethuba lidlula kwinqanaba lesisu, litshisa i-potassium. Kwiimvavanyo zesikliniki, i-Patiromer iboniswe ukuba ikhuselekile kwaye isebenzayo kwiiveki ezingama-52 kubantu abane-hyperkalemia kunye nesifo sikashukela, esibonisa ukuba yonyango lokulondolozwa okuthembisayo. Ngamanye amazwi, abantu abathatha i-RAAS inhibitors banokuphepha i-hyperkalemia ngokuthatha iPatiromer. Ngaphezu koko, emva kokuba abathathi-nxaxheba bayeke ukuthabatha i-Patiromer, baphinde bahlakulela kwakhona i-hyperkalemia kwakhona. Kwinqaku ehambelanayo, kwezinye iiprogram, i-Patiromer iye yaboniswa ukukhusela i-hyperkalemia kubantu abanesifo senhliziyo ababethabatha i-RAAS inhibitors.
Izigulana ezithatha i-Patiromer zabika ezinye iziphumo ezinobungozi eziquka ukugqithisa kwezifo zesifo esingasasigxina, i-hypomagnesemia, ukunyuka koxinzelelo lwexinzelelo kunye nokuxinzelela kwemizimba. Kodwa ke, ke, iipesenti ezili-10 kuphela zabathathi-nxaxheba kulolu cwaningo bayeka ukuthatha i-Patiromer ngenxa yale miphumo emibi.
Nangona isithembiso esibonakaliswe yi-Patiromer ngexesha lovavanyo lweSigaba sesi-3, ezinye iingcali zivakalise ukuxhalabisa malunga neziyobisi. Okokuqala, ezi ngcali zibonisa ukuba kuya kuba yinto efanelekileyo yokuqhubeka nokuvavanywa kwe-Patiromer ixesha elide ngaphezu konyaka - emva koko, abanye abantu baya kufuna ukuchitha intsali yobomi babo kwi-Patiromer ngelixa befumana i-RAAS inhibitors.
Okwesibini, akucaci ukuba ngaba abantu bathatha i-RAAS inhibitors kunye ne-Patiromer ye-hyperkalemia bayazuza kwiinkatho nge-RAAS inhibitors njengalezo ezinamazinga aqhelekileyo e-potassium (normokalemia) abathatha i-RAAS inhibitors.
Ukuba unemibuzo malunga nePatiromer okanye nawaphi na amayeza, nceda wenze ixesha lokuba uqhagamshelane nale nkxalabo nodokotela wakho. Nceda ukhumbule ukuba ugqirha wakho ungumnakekeli onobubele omele ujonge ukukunceda uhlale unolwazi kwaye unolwazi. Ukufunda malunga neziyobisi kunye neyeza kwi-Intanethi kuyindlela efanelekileyo yokuzigcina unolwazi. Nangona kunjalo, olu lwazi lufanele luzalise ukunyamekela kunye neengcebiso ezinikezelwa ngugqirha wakho.
> Imithombo:
> "Impembelelo ye-Patiromer kwiSerum Potassium Level in Patients With Hyperkalemia and Diabetes Disease Disease I-AMETHYST-DN I-Trial Clinic Trial" ngo-GL Bakris kunye nabalobi bezobambiswano ezipapashwe kwi-JAMA ngo-2015.
> "Ukwelashwa kwe-Hyperkalemia Ukusuka kwi-Hyper K +" Ukuqhutyelwa kweKhaya ukuya kuKhaya? " nguWC Winklemayer opapashwe kwi-JAMA ngo-2015.